The current weight of an inpatient should be documented on EMR Note : Dose 2 is given 3 weeks after dose 1 and then 4 weekly for the remainder of RSV season. Preparation: Palivizumab is listed in Table 1 of the RCH Hazardous Drugs list, and as a result a respiratory mask and protective eyewear must be worn for tasks that pose an increased risk of internalization or splash. Palivizumab for injection is available as: 50mg vial 0. The vial top must be disinfected before drawing up each dose.
Some strategies that are recommended during administration of the Injection include: Oral sucrose infants Breastfeeding Shaking a noisy toy Topical anaesthetic agents, such as AnGel or EMLA cream can also be used. Post Vaccination Immediate after care Dispose of clinical and sharps waste Cover the injection site with cotton wool and tape as needed Gently apply pressure for minutes do not rub injection site, as it may lead to localised irritation As with any IM injection, caution should be used when administering Palivizumab to patients with thrombocytopenia or anticoagulation.
Firm pressure should be applied for approximately minutes. After procedure perform hand hygiene Inform parent to remain in the hospital with the child for at least 15 minutes after receiving the Palivizumab to observe for any immediate adverse event Adverse Events An adverse event is any untoward medical occurrence that follows medication administration and does not necessarily have a causal relationship with the usage of the Palivizumab.
The most serious adverse event is anaphylaxis. Nursing staff must be aware of anaphylaxis management. Any adverse event should be reported to the Immunisation service and can be contacted on Option 3. Details which should be recorded include Medication given Including brand name, batch number, dose number Date and time of injection Site of administration Name of the person who administered the injection.
Evidence Table The evidence table for this guideline can be found here. In August , the Academy published the most recent guidelines to assist with identification of young children at increased risk of RSV hospitalization and most likely to benefit from prophylaxis. For a complete discussion of the basis for each recommendation, see the AAP policy statement Pediatrics. Following recent reviews by the Committee on Infectious Diseases and the Subcommittee on Bronchiolitis, these recommendations remain unchanged from A summary of current recommendations is presented here.
Detailed input regarding current guidelines was solicited from 21 AAP committees, councils, sections and advisory groups as well as from organizations outside the Academy.
The Committee on Infectious Diseases and the Subcommittee on Bronchiolitis regularly review and evaluate all data and as they become available. In September , all available data regarding palivizumab were considered, and both groups reaffirmed the recommendations in the RSV policy statement and technical report. Advertising Disclaimer ».
Sign In or Create an Account. Search Close. Create Account. Advanced Search. Skip Nav Destination Share. Flor M. Munoz, M. Ralston, M. SYNAGIS, 50 mg and mg for injection, is a prescription medication that is used to help prevent a serious lung disease caused by respiratory syncytial virus RSV in children:. Registration Successful HS-CHD stands for hemodynamically significant congenital heart disease.
What are the side effects?
0コメント